Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof

• US 20060019907A1
• Filed: 07/12/2005
• Published: 01/26/2006
• Est. Priority Date: 07/12/2004
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Research & Development Foundation
• Inventors: Aggarwal, Bharat B., Shishodia, Shishir
• Application Number:
  US11/179,321
• Publication Number:
  US 20060019907A1
• Time in Patent Office: Days
• US Class Current: 514/26
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides an inhibitor of NF-κB, guggulsterone and its analogs. Guggulsterone suppresses NF-κB activation induced by TNF, phorbol ester, okadaic acid, cigarette smoke, H₂O₂ and IL-1β, as well as constitutive NF-κB activation expressed in most tumor cells. One mechanism by which guggulsterone inhibits activation of NF-κB is through suppression of IκBα phosphorylation and IκBα degradation. NF-κB-dependent gene transcription is modulated by guggulsterone and its analogs. In particular, induction by TNF, TNFR1, TRADD, TRAF2, NIK and IKK, is modulated by guggulsterone and its analogs. In addition, guggulsterone decreased the expression of genes involved in anti-apoptosis (IAP1, XIAP, Bfl-1/A1, bcl-2, cFLIP, survivin), proliferation (cyclin D1, c-myc) and metastasis (MMP-9, COX2 and VEGF).

Claims

1. A method of inhibiting activation of NF-κ

B in a cell, comprising the step of contacting the cell with guggulsterone or a guggulsterone analog, wherein guggulsterone or guggulsterone analog suppresses NF-κ

B activation.

2. The method of claim 1, wherein the NF-κ

B activation is induced by a carcinogen, an inflammatory stimulus, or both a carcinogen and an inflammatory stimulus.

3. The method of claim 2, wherein the carcinogen is selected from the group consisting of phorbol ester, okadaic acid, and cigarette smoke.

4. The method of claim 2, wherein the inflammatory stimulus is selected from the group consisting of hydrogen peroxide, TNF, and IL-1β

.

5. The method of claim 1, wherein the NF-κ

B activation is constitutive.

6. The method of claim 1, wherein the suppression of NF-κ

B activation is through inhibition of Akt kinase;

inhibition of Iκ

Bα

kinase;

Iκ

Bα

phosphorylation;

Iκ

Bα

degradation;

p65 phosphorylation and nuclear translocation;

or combinations thereof.

7. The method of claim 1, wherein the suppression of NF-κ

B activation by guggulsterone or guggulsterone analog abrogates NF-κ

B-dependent gene transcription induced by TNF, TNF receptor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-κ

B-inducing kinase, Iκ

Bα

kinase, or any combination thereof.

8. A method of downregulating gene expression in a cell, comprising the step of contacting the cell with guggulsterone or a guggulsterone analog, wherein guggulsterone or guggulsterone analog suppresses NF-κ

B activation and the suppression of NF-κ

B activation down-regulates the expression of anti-apoptotic genes, proliferative genes, metastasis genes, or combinations thereof.

9. The method of claim 8, wherein the anti-apoptotic gene is selected from the group consisting of IAP1, XIAP, Bfl-1/A1, bcl-2, cFLIP and survivin.

10. The method of claim 8, wherein the proliferative gene is cyclin D1, c-myc, or cyclin D1 and c-myc.

11. The method of claim 8, wherein the metastasis gene is selected from the group consisting of MMP-9, COX-2 and VEGF.

12. A method of enhancing the effect of an apoptosis-inducing agent in a cell, comprising the step of contacting the cell with the apoptosis-inducing agent, and guggulsterone or a guggulsterone analog, wherein inhibition of NF-κ

B activation by guggulsterone results in enhanced apoptosis.

13. The method of claim 12, wherein the apoptosis-inducing agent is TNF, a cancer therapeutic, a chemotherapeutic agent, or a combination thereof.

14. The method of claim 13, wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, gemcitabine, 5-Flurouracil, etoposide, cisplatin, campothecin, and vincristine.

15. A method of treating a cancerous or pre-cancerous state in an individual in need of such treatment, comprising the step of administering a pharmacologically effective dose of guggulsterone to the individual.

16. The method of claim 15, further comprising the step of administering a non-guggulsterone inhibitor of the activation of NF-κ

B, wherein the non-guggulsterone inhibitor is selected from the group consisting of curcumin, CAPE, capsaicin, sanguinarin, PTPase inhibitors, lapachone, resveratrol, vesnarinone, leflunomide, anethole, PI3 kinase inhibitors, oleanderin, emodin, serine protease inhibitors, protein tyrosine kinase inhibitors, thalidomide and methotrexate.

18. The method of claim 15, wherein the cancerous or pre-cancerous state is characterized by at least one cell having constitutive activation of NF-κ

B.

19. The method of claim 15, wherein the cancerous or pre-cancerous state is selected from the group consisting of breast cancer, prostate cancer, melanoma, pancreatic cancer, colon cancer, leukemia and multiple myeloma.

20. A method of increasing cytotoxic effects of a chemotherapeutic agent against cancer in an individual, comprising the step of administering to the individual the chemotherapeutic agent and an inhibitor of the activation of NF-κ

B, wherein the inhibitor of the activation of NF-κ

B increases the cytotoxic effects of the chemotherapeutic agent against cancer cells in the individual.

21. The method of claim 20, wherein the inhibitor of the activation of NF-κ

B is selected from the group consisting of guggulsterone, guggulsterone analog, curcumin, CAPE, capsaicin, sanguinarin, PTPase inhibitors, lapachone, resveratrol, vesnarinone, leflunomide, anethole, PI3 kinase inhibitors, oleanderin, emodin, serine protease inhibitors, protein tyrosine kinase inhibitors, thalidomide and methotrexate.

23. The method of claim 20, wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, gemcitabine, 5-Flurouracil, etoposide, cisplatin, campothecin, and vincristine.

24. The method of claim 20, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, melanoma, pancreatic cancer, colon cancer, leukemia and multiple myeloma.

25. A method of inhibiting osteoclastogenesis comprising the step of contacting the cell with guggulsterone or a guggulsterone analog, wherein guggulsterone or guggulsterone analog suppresses NF-κ

B activation and osteoclastogenesis.

26. The method of claim 25, wherein the NF-κ

B activation and osteoclastogenesis is induced by RANKL.